Last $57.18 USD
Change Today +0.09 / 0.16%
Volume 913.8K
TEVA On Other Exchanges
New York
Tel Aviv
As of 8:04 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Basel Street

Petach Tikva, 49131


Phone: 972 3 926 7267

Fax: 972 3 923 4050

ajor markets. Canada In Canada, the company manufactures and markets prescription pharmaceuticals. Its generic product portfolio includes approximately 300 products in various dosage forms and packaging sizes. The company’s generic sales force in Canada markets generic products to retail chains, retail buying groups and independent pharmacies, reaching approximately 8,800 outlets across Canada. The company provides professional healthcare products and services in the Israeli market. In addition to generic and specialty pharmaceutical products, it sells and distributes a range of healthcare products and services in Israel. The company’s distribution company provides logistical support and distributes third-party products. Specialty Medicines This segment includes various core franchises, most significantly medicines for central nervous system (CNS) disorders (with a emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines, as well as other areas such as oncology and women’s health. The company’s specialty business also includes its emerging NTE activity. The company’s specialty medicines business, which is focused on delivering solutions to patients and providers through medicines, devices and services in all key regions and markets around the world, includes core therapeutic areas, most significantly medicines for CNS disorders (with a emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines. The company also has specialty products in oncology, women’s health and other areas. Its specialty business also includes its emerging NTE activity, which focuses on enhancing known molecules through new delivery methods, unique combinations or device innovations to address specific patient needs. CNS The company’s CNS portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson’s disease and Nuvigil for the treatment of sleep disorders, as well as novel therapies for the treatment of pain. Copaxone (glatiramer acetate injection), the company’s major specialty medicine, is the multiple sclerosis therapy worldwide and is approved in approximately 50 countries, including the United States, all European countries, Russia, Canada, major Latin American markets, Australia and Israel. Copaxone is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis (RRMS), including in patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis. Multiple sclerosis is the most common cause of neurological disability in young adults and affects approximately 2.5 million people worldwide. In the majority of patients, the disease is of the relapsing-remitting form, which is manifested by relapses and slow progression of the disease that can affect the functioning of multiple systems. The company’s MS portfolio consists of Copaxone, as well as laquinimod, a Phase III investigational compound under development. Copaxone is a non-interferon immunomodulator approved for the treatment of RRMS. Copaxone provides a proven mix of efficacy, safety and tolerability. The company’s U.S. Orange Book patents covering Copaxone expire in May 2014. It has patents expiring in May 2015 in most of the rest of the world. Azilect: The company jointly markets Azilect (rasagiline tablets) with Lundbeck in certain key European countries. It markets Azilect in the United States and Germany and certain other markets, while Lundbeck markets Azilect in the remaining European countries and certain other international markets. The company offers Nuvigil and Provigil. Oncology Products The company’s specialty oncology product line includes Treanda, Synribo, and certain other products, as well as its biosimilar products indicated mainly for the treatment of side effects of oncology treatments. The company launched new Granulocyte Colony Stimulating Factor (G-CSF) products in both the United States and Europe. Respiratory Products The company’s respiratory product line includes its specialty respiratory products, mainly ProAir, Qvar and Qn


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVA:US $57.18 USD +0.09

TEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $66.98 USD +0.77
Actavis plc $257.09 USD +2.89
Baxter International Inc $74.56 USD +0.11
Eli Lilly & Co $70.39 USD +0.23
Valeant Pharmaceuticals International Inc C$163.19 CAD -0.41
View Industry Companies

Industry Analysis


Industry Average

Valuation TEVA Industry Range
Price/Earnings 17.8x
Price/Sales 2.4x
Price/Book 2.1x
Price/Cash Flow 19.9x
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at